nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—systemic lupus erythematosus	0.23	0.678	CbGaD
Thalidomide—PTGS2—systemic lupus erythematosus	0.109	0.322	CbGaD
Thalidomide—PTGS2—Dapsone—systemic lupus erythematosus	0.0341	0.101	CbGbCtD
Thalidomide—PTGS2—Triamcinolone—systemic lupus erythematosus	0.0295	0.0876	CbGbCtD
Thalidomide—PTGS1—Dapsone—systemic lupus erythematosus	0.0288	0.0853	CbGbCtD
Thalidomide—PTGS2—Betamethasone—systemic lupus erythematosus	0.0253	0.0751	CbGbCtD
Thalidomide—CYP2E1—Dapsone—systemic lupus erythematosus	0.0222	0.0659	CbGbCtD
Thalidomide—CYP1A2—Leflunomide—systemic lupus erythematosus	0.018	0.0535	CbGbCtD
Thalidomide—CYP3A5—Dapsone—systemic lupus erythematosus	0.0173	0.0512	CbGbCtD
Thalidomide—CYP2C9—Leflunomide—systemic lupus erythematosus	0.0162	0.0482	CbGbCtD
Thalidomide—CYP3A5—Mycophenolate mofetil—systemic lupus erythematosus	0.015	0.0444	CbGbCtD
Thalidomide—PTGS2—Dexamethasone—systemic lupus erythematosus	0.0147	0.0437	CbGbCtD
Thalidomide—CYP2C19—Dapsone—systemic lupus erythematosus	0.0139	0.0413	CbGbCtD
Thalidomide—CYP1A1—Dexamethasone—systemic lupus erythematosus	0.0124	0.0369	CbGbCtD
Thalidomide—CYP3A5—Hydrocortisone—systemic lupus erythematosus	0.012	0.0356	CbGbCtD
Thalidomide—CYP2C9—Dapsone—systemic lupus erythematosus	0.0116	0.0343	CbGbCtD
Thalidomide—CYP3A5—Cyclosporine—systemic lupus erythematosus	0.0113	0.0336	CbGbCtD
Thalidomide—CYP2C19—Prednisone—systemic lupus erythematosus	0.00965	0.0286	CbGbCtD
Thalidomide—CYP2E1—Dexamethasone—systemic lupus erythematosus	0.00961	0.0285	CbGbCtD
Thalidomide—CYP2C19—Cyclosporine—systemic lupus erythematosus	0.00915	0.0271	CbGbCtD
Thalidomide—CYP2C9—Cyclosporine—systemic lupus erythematosus	0.00761	0.0226	CbGbCtD
Thalidomide—CYP3A5—Dexamethasone—systemic lupus erythematosus	0.00747	0.0222	CbGbCtD
Thalidomide—CYP2C9—cardial valve—systemic lupus erythematosus	0.00615	0.13	CbGeAlD
Thalidomide—CYP2C19—Dexamethasone—systemic lupus erythematosus	0.00603	0.0179	CbGbCtD
Thalidomide—CYP2C9—Dexamethasone—systemic lupus erythematosus	0.00501	0.0149	CbGbCtD
Thalidomide—CYP2C19—urine—systemic lupus erythematosus	0.00171	0.0363	CbGeAlD
Thalidomide—NFKB1—connective tissue—systemic lupus erythematosus	0.00141	0.0299	CbGeAlD
Thalidomide—CYP1A2—urine—systemic lupus erythematosus	0.0014	0.0296	CbGeAlD
Thalidomide—CYP2C9—urine—systemic lupus erythematosus	0.00133	0.0281	CbGeAlD
Thalidomide—CYP2E1—urine—systemic lupus erythematosus	0.00126	0.0266	CbGeAlD
Thalidomide—NFKB1—kidney—systemic lupus erythematosus	0.0012	0.0254	CbGeAlD
Thalidomide—NFKB1—cortex of kidney—systemic lupus erythematosus	0.00117	0.0248	CbGeAlD
Thalidomide—Pomalidomide—TNF—systemic lupus erythematosus	0.00116	0.346	CrCbGaD
Thalidomide—CRBN—nephron tubule—systemic lupus erythematosus	0.00114	0.0243	CbGeAlD
Thalidomide—FGFR2—connective tissue—systemic lupus erythematosus	0.00106	0.0224	CbGeAlD
Thalidomide—Menadione—F2—systemic lupus erythematosus	0.00105	0.314	CrCbGaD
Thalidomide—NFKB1—lymphoid tissue—systemic lupus erythematosus	0.00103	0.0218	CbGeAlD
Thalidomide—CRBN—cortex of kidney—systemic lupus erythematosus	0.000979	0.0208	CbGeAlD
Thalidomide—NFKB1—tendon—systemic lupus erythematosus	0.000968	0.0205	CbGeAlD
Thalidomide—FGFR2—skin of body—systemic lupus erythematosus	0.000955	0.0203	CbGeAlD
Thalidomide—NFKB1—bone marrow—systemic lupus erythematosus	0.000938	0.0199	CbGeAlD
Thalidomide—FGFR2—kidney—systemic lupus erythematosus	0.000901	0.0191	CbGeAlD
Thalidomide—CYP2C19—blood plasma—systemic lupus erythematosus	0.000893	0.0189	CbGeAlD
Thalidomide—CRBN—lymphoid tissue—systemic lupus erythematosus	0.000863	0.0183	CbGeAlD
Thalidomide—NFKB1—lung—systemic lupus erythematosus	0.00085	0.018	CbGeAlD
Thalidomide—CRBN—tendon—systemic lupus erythematosus	0.000812	0.0172	CbGeAlD
Thalidomide—NFKB1—nervous system—systemic lupus erythematosus	0.000787	0.0167	CbGeAlD
Thalidomide—CRBN—bone marrow—systemic lupus erythematosus	0.000786	0.0167	CbGeAlD
Thalidomide—NFKB1—central nervous system—systemic lupus erythematosus	0.000758	0.0161	CbGeAlD
Thalidomide—CYP1A2—blood plasma—systemic lupus erythematosus	0.000729	0.0155	CbGeAlD
Thalidomide—CRBN—lung—systemic lupus erythematosus	0.000712	0.0151	CbGeAlD
Thalidomide—PTGS1—endothelium—systemic lupus erythematosus	0.000711	0.0151	CbGeAlD
Thalidomide—CYP3A5—blood plasma—systemic lupus erythematosus	0.000703	0.0149	CbGeAlD
Thalidomide—CYP2C9—blood plasma—systemic lupus erythematosus	0.000692	0.0147	CbGeAlD
Thalidomide—PTGS2—endothelium—systemic lupus erythematosus	0.00068	0.0144	CbGeAlD
Thalidomide—CRBN—nervous system—systemic lupus erythematosus	0.00066	0.014	CbGeAlD
Thalidomide—CYP2E1—blood plasma—systemic lupus erythematosus	0.000656	0.0139	CbGeAlD
Thalidomide—FGFR2—lung—systemic lupus erythematosus	0.000638	0.0135	CbGeAlD
Thalidomide—CRBN—central nervous system—systemic lupus erythematosus	0.000635	0.0135	CbGeAlD
Thalidomide—PTGS1—blood plasma—systemic lupus erythematosus	0.000632	0.0134	CbGeAlD
Thalidomide—PTGS2—blood plasma—systemic lupus erythematosus	0.000604	0.0128	CbGeAlD
Thalidomide—Lenalidomide—PTGS2—systemic lupus erythematosus	0.000592	0.177	CrCbGaD
Thalidomide—FGFR2—nervous system—systemic lupus erythematosus	0.000591	0.0125	CbGeAlD
Thalidomide—FGFR2—central nervous system—systemic lupus erythematosus	0.000569	0.0121	CbGeAlD
Thalidomide—Pomalidomide—PTGS2—systemic lupus erythematosus	0.00055	0.164	CrCbGaD
Thalidomide—CYP3A5—nephron tubule—systemic lupus erythematosus	0.000363	0.00769	CbGeAlD
Thalidomide—CYP1A1—skin of body—systemic lupus erythematosus	0.000346	0.00733	CbGeAlD
Thalidomide—CYP2E1—nephron tubule—systemic lupus erythematosus	0.000338	0.00717	CbGeAlD
Thalidomide—PTGS1—connective tissue—systemic lupus erythematosus	0.000336	0.00713	CbGeAlD
Thalidomide—PTGS2—Fluocinonide—Methylprednisolone—systemic lupus erythematosus	0.000336	0.159	CbGdCrCtD
Thalidomide—PTGS2—Fluocinonide—Betamethasone—systemic lupus erythematosus	0.00033	0.156	CbGdCrCtD
Thalidomide—PTGS2—Fluocinonide—Dexamethasone—systemic lupus erythematosus	0.00033	0.156	CbGdCrCtD
Thalidomide—CYP1A1—kidney—systemic lupus erythematosus	0.000326	0.00691	CbGeAlD
Thalidomide—PTGS2—Fluocinonide—Triamcinolone—systemic lupus erythematosus	0.000323	0.153	CbGdCrCtD
Thalidomide—PTGS2—connective tissue—systemic lupus erythematosus	0.000321	0.00682	CbGeAlD
Thalidomide—CYP3A5—kidney—systemic lupus erythematosus	0.000319	0.00676	CbGeAlD
Thalidomide—CYP3A5—cortex of kidney—systemic lupus erythematosus	0.00031	0.00658	CbGeAlD
Thalidomide—PTGS1—skin of body—systemic lupus erythematosus	0.000304	0.00644	CbGeAlD
Thalidomide—CYP2E1—kidney—systemic lupus erythematosus	0.000297	0.0063	CbGeAlD
Thalidomide—PTGS2—skin of body—systemic lupus erythematosus	0.00029	0.00616	CbGeAlD
Thalidomide—CYP2E1—cortex of kidney—systemic lupus erythematosus	0.000289	0.00614	CbGeAlD
Thalidomide—PTGS1—kidney—systemic lupus erythematosus	0.000286	0.00607	CbGeAlD
Thalidomide—PTGS2—kidney—systemic lupus erythematosus	0.000274	0.0058	CbGeAlD
Thalidomide—CYP2E1—lymphoid tissue—systemic lupus erythematosus	0.000255	0.00541	CbGeAlD
Thalidomide—CYP2E1—tendon—systemic lupus erythematosus	0.00024	0.00509	CbGeAlD
Thalidomide—PTGS2—lymphoid tissue—systemic lupus erythematosus	0.000235	0.00498	CbGeAlD
Thalidomide—CYP1A2—lung—systemic lupus erythematosus	0.000234	0.00496	CbGeAlD
Thalidomide—PTGS1—tendon—systemic lupus erythematosus	0.000231	0.0049	CbGeAlD
Thalidomide—CYP1A1—lung—systemic lupus erythematosus	0.000231	0.0049	CbGeAlD
Thalidomide—CYP3A5—lung—systemic lupus erythematosus	0.000226	0.00479	CbGeAlD
Thalidomide—PTGS2—tendon—systemic lupus erythematosus	0.000221	0.00469	CbGeAlD
Thalidomide—PTGS2—bone marrow—systemic lupus erythematosus	0.000214	0.00454	CbGeAlD
Thalidomide—CYP1A1—nervous system—systemic lupus erythematosus	0.000214	0.00453	CbGeAlD
Thalidomide—CYP2E1—lung—systemic lupus erythematosus	0.000211	0.00447	CbGeAlD
Thalidomide—CYP1A1—central nervous system—systemic lupus erythematosus	0.000206	0.00437	CbGeAlD
Thalidomide—PTGS1—lung—systemic lupus erythematosus	0.000203	0.0043	CbGeAlD
Thalidomide—PTGS2—Fluticasone Propionate—Methylprednisolone—systemic lupus erythematosus	0.000202	0.0958	CbGdCrCtD
Thalidomide—PTGS2—Fluticasone Propionate—Betamethasone—systemic lupus erythematosus	0.000199	0.0943	CbGdCrCtD
Thalidomide—PTGS2—Fluticasone Propionate—Dexamethasone—systemic lupus erythematosus	0.000199	0.0943	CbGdCrCtD
Thalidomide—CYP2E1—nervous system—systemic lupus erythematosus	0.000195	0.00414	CbGeAlD
Thalidomide—PTGS2—Fluticasone Propionate—Triamcinolone—systemic lupus erythematosus	0.000195	0.0921	CbGdCrCtD
Thalidomide—PTGS2—lung—systemic lupus erythematosus	0.000194	0.00411	CbGeAlD
Thalidomide—PTGS1—nervous system—systemic lupus erythematosus	0.000188	0.00398	CbGeAlD
Thalidomide—CYP2E1—central nervous system—systemic lupus erythematosus	0.000188	0.00398	CbGeAlD
Thalidomide—PTGS1—central nervous system—systemic lupus erythematosus	0.000181	0.00384	CbGeAlD
Thalidomide—PTGS2—nervous system—systemic lupus erythematosus	0.00018	0.00381	CbGeAlD
Thalidomide—PTGS2—central nervous system—systemic lupus erythematosus	0.000173	0.00367	CbGeAlD
Thalidomide—Urethral disorder—Methotrexate—systemic lupus erythematosus	3.81e-05	0.00025	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Triamcinolone—systemic lupus erythematosus	3.81e-05	0.00025	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Methylprednisolone—systemic lupus erythematosus	3.8e-05	0.00025	CcSEcCtD
Thalidomide—Pain—Hydrocortisone—systemic lupus erythematosus	3.8e-05	0.00025	CcSEcCtD
Thalidomide—Oedema—Dexamethasone—systemic lupus erythematosus	3.8e-05	0.000249	CcSEcCtD
Thalidomide—Oedema—Betamethasone—systemic lupus erythematosus	3.8e-05	0.000249	CcSEcCtD
Thalidomide—Insomnia—Triamcinolone—systemic lupus erythematosus	3.79e-05	0.000249	CcSEcCtD
Thalidomide—Insomnia—Methylprednisolone—systemic lupus erythematosus	3.78e-05	0.000248	CcSEcCtD
Thalidomide—Infection—Betamethasone—systemic lupus erythematosus	3.77e-05	0.000248	CcSEcCtD
Thalidomide—Infection—Dexamethasone—systemic lupus erythematosus	3.77e-05	0.000248	CcSEcCtD
Thalidomide—Ill-defined disorder—Prednisone—systemic lupus erythematosus	3.76e-05	0.000247	CcSEcCtD
Thalidomide—Paraesthesia—Triamcinolone—systemic lupus erythematosus	3.76e-05	0.000247	CcSEcCtD
Thalidomide—Feeling abnormal—Prednisolone—systemic lupus erythematosus	3.75e-05	0.000246	CcSEcCtD
Thalidomide—Paraesthesia—Methylprednisolone—systemic lupus erythematosus	3.75e-05	0.000246	CcSEcCtD
Thalidomide—Visual impairment—Methotrexate—systemic lupus erythematosus	3.75e-05	0.000246	CcSEcCtD
Thalidomide—Anaemia—Prednisone—systemic lupus erythematosus	3.75e-05	0.000246	CcSEcCtD
Thalidomide—Shock—Betamethasone—systemic lupus erythematosus	3.74e-05	0.000245	CcSEcCtD
Thalidomide—Shock—Dexamethasone—systemic lupus erythematosus	3.74e-05	0.000245	CcSEcCtD
Thalidomide—Dyspnoea—Triamcinolone—systemic lupus erythematosus	3.73e-05	0.000245	CcSEcCtD
Thalidomide—Nervous system disorder—Dexamethasone—systemic lupus erythematosus	3.72e-05	0.000245	CcSEcCtD
Thalidomide—Nervous system disorder—Betamethasone—systemic lupus erythematosus	3.72e-05	0.000245	CcSEcCtD
Thalidomide—Agitation—Prednisone—systemic lupus erythematosus	3.72e-05	0.000245	CcSEcCtD
Thalidomide—Thrombocytopenia—Betamethasone—systemic lupus erythematosus	3.72e-05	0.000244	CcSEcCtD
Thalidomide—Thrombocytopenia—Dexamethasone—systemic lupus erythematosus	3.72e-05	0.000244	CcSEcCtD
Thalidomide—Tachycardia—Betamethasone—systemic lupus erythematosus	3.71e-05	0.000243	CcSEcCtD
Thalidomide—Tachycardia—Dexamethasone—systemic lupus erythematosus	3.71e-05	0.000243	CcSEcCtD
Thalidomide—Angioedema—Prednisone—systemic lupus erythematosus	3.7e-05	0.000243	CcSEcCtD
Thalidomide—Hypersensitivity—Cyclosporine—systemic lupus erythematosus	3.68e-05	0.000242	CcSEcCtD
Thalidomide—Dyspepsia—Triamcinolone—systemic lupus erythematosus	3.68e-05	0.000242	CcSEcCtD
Thalidomide—Erythema multiforme—Methotrexate—systemic lupus erythematosus	3.68e-05	0.000242	CcSEcCtD
Thalidomide—Dyspepsia—Methylprednisolone—systemic lupus erythematosus	3.68e-05	0.000241	CcSEcCtD
Thalidomide—Hyperhidrosis—Betamethasone—systemic lupus erythematosus	3.67e-05	0.000241	CcSEcCtD
Thalidomide—Hyperhidrosis—Dexamethasone—systemic lupus erythematosus	3.67e-05	0.000241	CcSEcCtD
Thalidomide—Feeling abnormal—Hydrocortisone—systemic lupus erythematosus	3.66e-05	0.000241	CcSEcCtD
Thalidomide—Malaise—Prednisone—systemic lupus erythematosus	3.65e-05	0.00024	CcSEcCtD
Thalidomide—Vertigo—Prednisone—systemic lupus erythematosus	3.64e-05	0.000239	CcSEcCtD
Thalidomide—Eye disorder—Methotrexate—systemic lupus erythematosus	3.64e-05	0.000239	CcSEcCtD
Thalidomide—Gastrointestinal pain—Hydrocortisone—systemic lupus erythematosus	3.63e-05	0.000239	CcSEcCtD
Thalidomide—Syncope—Prednisone—systemic lupus erythematosus	3.63e-05	0.000239	CcSEcCtD
Thalidomide—Tinnitus—Methotrexate—systemic lupus erythematosus	3.63e-05	0.000238	CcSEcCtD
Thalidomide—Anorexia—Dexamethasone—systemic lupus erythematosus	3.62e-05	0.000238	CcSEcCtD
Thalidomide—Anorexia—Betamethasone—systemic lupus erythematosus	3.62e-05	0.000238	CcSEcCtD
Thalidomide—Urticaria—Prednisolone—systemic lupus erythematosus	3.62e-05	0.000237	CcSEcCtD
Thalidomide—Cardiac disorder—Methotrexate—systemic lupus erythematosus	3.61e-05	0.000237	CcSEcCtD
Thalidomide—Fatigue—Triamcinolone—systemic lupus erythematosus	3.61e-05	0.000237	CcSEcCtD
Thalidomide—Fatigue—Methylprednisolone—systemic lupus erythematosus	3.6e-05	0.000236	CcSEcCtD
Thalidomide—Hypersensitivity—Mycophenolate mofetil—systemic lupus erythematosus	3.59e-05	0.000236	CcSEcCtD
Thalidomide—Asthenia—Cyclosporine—systemic lupus erythematosus	3.59e-05	0.000236	CcSEcCtD
Thalidomide—Pain—Triamcinolone—systemic lupus erythematosus	3.58e-05	0.000235	CcSEcCtD
Thalidomide—Loss of consciousness—Prednisone—systemic lupus erythematosus	3.56e-05	0.000234	CcSEcCtD
Thalidomide—Hypotension—Betamethasone—systemic lupus erythematosus	3.55e-05	0.000233	CcSEcCtD
Thalidomide—Hypotension—Dexamethasone—systemic lupus erythematosus	3.55e-05	0.000233	CcSEcCtD
Thalidomide—Pruritus—Cyclosporine—systemic lupus erythematosus	3.54e-05	0.000232	CcSEcCtD
Thalidomide—Urticaria—Hydrocortisone—systemic lupus erythematosus	3.53e-05	0.000232	CcSEcCtD
Thalidomide—Angiopathy—Methotrexate—systemic lupus erythematosus	3.53e-05	0.000232	CcSEcCtD
Thalidomide—Immune system disorder—Methotrexate—systemic lupus erythematosus	3.51e-05	0.000231	CcSEcCtD
Thalidomide—Body temperature increased—Hydrocortisone—systemic lupus erythematosus	3.51e-05	0.000231	CcSEcCtD
Thalidomide—Abdominal pain—Hydrocortisone—systemic lupus erythematosus	3.51e-05	0.000231	CcSEcCtD
Thalidomide—Convulsion—Prednisone—systemic lupus erythematosus	3.51e-05	0.000231	CcSEcCtD
Thalidomide—Mediastinal disorder—Methotrexate—systemic lupus erythematosus	3.51e-05	0.00023	CcSEcCtD
Thalidomide—Asthenia—Mycophenolate mofetil—systemic lupus erythematosus	3.5e-05	0.00023	CcSEcCtD
Thalidomide—Hypertension—Prednisone—systemic lupus erythematosus	3.5e-05	0.00023	CcSEcCtD
Thalidomide—Chills—Methotrexate—systemic lupus erythematosus	3.49e-05	0.000229	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Dexamethasone—systemic lupus erythematosus	3.46e-05	0.000227	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Betamethasone—systemic lupus erythematosus	3.46e-05	0.000227	CcSEcCtD
Thalidomide—Pruritus—Mycophenolate mofetil—systemic lupus erythematosus	3.45e-05	0.000227	CcSEcCtD
Thalidomide—Arthralgia—Prednisone—systemic lupus erythematosus	3.45e-05	0.000227	CcSEcCtD
Thalidomide—Myalgia—Prednisone—systemic lupus erythematosus	3.45e-05	0.000227	CcSEcCtD
Thalidomide—Feeling abnormal—Triamcinolone—systemic lupus erythematosus	3.45e-05	0.000226	CcSEcCtD
Thalidomide—Feeling abnormal—Methylprednisolone—systemic lupus erythematosus	3.44e-05	0.000226	CcSEcCtD
Thalidomide—Anxiety—Prednisone—systemic lupus erythematosus	3.44e-05	0.000226	CcSEcCtD
Thalidomide—Alopecia—Methotrexate—systemic lupus erythematosus	3.44e-05	0.000226	CcSEcCtD
Thalidomide—Insomnia—Betamethasone—systemic lupus erythematosus	3.43e-05	0.000226	CcSEcCtD
Thalidomide—Insomnia—Dexamethasone—systemic lupus erythematosus	3.43e-05	0.000226	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic lupus erythematosus	3.43e-05	0.000225	CcSEcCtD
Thalidomide—Diarrhoea—Cyclosporine—systemic lupus erythematosus	3.42e-05	0.000225	CcSEcCtD
Thalidomide—Gastrointestinal pain—Methylprednisolone—systemic lupus erythematosus	3.41e-05	0.000224	CcSEcCtD
Thalidomide—Paraesthesia—Dexamethasone—systemic lupus erythematosus	3.41e-05	0.000224	CcSEcCtD
Thalidomide—Paraesthesia—Betamethasone—systemic lupus erythematosus	3.41e-05	0.000224	CcSEcCtD
Thalidomide—Discomfort—Prednisone—systemic lupus erythematosus	3.41e-05	0.000224	CcSEcCtD
Thalidomide—Mental disorder—Methotrexate—systemic lupus erythematosus	3.41e-05	0.000224	CcSEcCtD
Thalidomide—Malnutrition—Methotrexate—systemic lupus erythematosus	3.39e-05	0.000222	CcSEcCtD
Thalidomide—Hypersensitivity—Prednisolone—systemic lupus erythematosus	3.35e-05	0.00022	CcSEcCtD
Thalidomide—Dyspepsia—Dexamethasone—systemic lupus erythematosus	3.34e-05	0.00022	CcSEcCtD
Thalidomide—Dyspepsia—Betamethasone—systemic lupus erythematosus	3.34e-05	0.00022	CcSEcCtD
Thalidomide—Diarrhoea—Mycophenolate mofetil—systemic lupus erythematosus	3.34e-05	0.000219	CcSEcCtD
Thalidomide—Urticaria—Triamcinolone—systemic lupus erythematosus	3.32e-05	0.000218	CcSEcCtD
Thalidomide—Urticaria—Methylprednisolone—systemic lupus erythematosus	3.32e-05	0.000218	CcSEcCtD
Thalidomide—Dysgeusia—Methotrexate—systemic lupus erythematosus	3.32e-05	0.000218	CcSEcCtD
Thalidomide—Body temperature increased—Triamcinolone—systemic lupus erythematosus	3.31e-05	0.000217	CcSEcCtD
Thalidomide—Dizziness—Cyclosporine—systemic lupus erythematosus	3.31e-05	0.000217	CcSEcCtD
Thalidomide—Oedema—Prednisone—systemic lupus erythematosus	3.31e-05	0.000217	CcSEcCtD
Thalidomide—Abdominal pain—Methylprednisolone—systemic lupus erythematosus	3.3e-05	0.000217	CcSEcCtD
Thalidomide—Decreased appetite—Betamethasone—systemic lupus erythematosus	3.3e-05	0.000217	CcSEcCtD
Thalidomide—Decreased appetite—Dexamethasone—systemic lupus erythematosus	3.3e-05	0.000217	CcSEcCtD
Thalidomide—Infection—Prednisone—systemic lupus erythematosus	3.29e-05	0.000216	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Dexamethasone—systemic lupus erythematosus	3.28e-05	0.000215	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Betamethasone—systemic lupus erythematosus	3.28e-05	0.000215	CcSEcCtD
Thalidomide—Back pain—Methotrexate—systemic lupus erythematosus	3.28e-05	0.000215	CcSEcCtD
Thalidomide—Hypersensitivity—Hydrocortisone—systemic lupus erythematosus	3.27e-05	0.000215	CcSEcCtD
Thalidomide—Fatigue—Dexamethasone—systemic lupus erythematosus	3.27e-05	0.000215	CcSEcCtD
Thalidomide—Fatigue—Betamethasone—systemic lupus erythematosus	3.27e-05	0.000215	CcSEcCtD
Thalidomide—Shock—Prednisone—systemic lupus erythematosus	3.25e-05	0.000214	CcSEcCtD
Thalidomide—Pain—Betamethasone—systemic lupus erythematosus	3.25e-05	0.000213	CcSEcCtD
Thalidomide—Pain—Dexamethasone—systemic lupus erythematosus	3.25e-05	0.000213	CcSEcCtD
Thalidomide—Nervous system disorder—Prednisone—systemic lupus erythematosus	3.24e-05	0.000213	CcSEcCtD
Thalidomide—Tachycardia—Prednisone—systemic lupus erythematosus	3.23e-05	0.000212	CcSEcCtD
Thalidomide—Dizziness—Mycophenolate mofetil—systemic lupus erythematosus	3.23e-05	0.000212	CcSEcCtD
Thalidomide—Skin disorder—Prednisone—systemic lupus erythematosus	3.21e-05	0.000211	CcSEcCtD
Thalidomide—Hyperhidrosis—Prednisone—systemic lupus erythematosus	3.2e-05	0.00021	CcSEcCtD
Thalidomide—Vision blurred—Methotrexate—systemic lupus erythematosus	3.19e-05	0.00021	CcSEcCtD
Thalidomide—Asthenia—Hydrocortisone—systemic lupus erythematosus	3.19e-05	0.000209	CcSEcCtD
Thalidomide—Vomiting—Cyclosporine—systemic lupus erythematosus	3.18e-05	0.000209	CcSEcCtD
Thalidomide—Rash—Cyclosporine—systemic lupus erythematosus	3.15e-05	0.000207	CcSEcCtD
Thalidomide—Anorexia—Prednisone—systemic lupus erythematosus	3.15e-05	0.000207	CcSEcCtD
Thalidomide—Dermatitis—Cyclosporine—systemic lupus erythematosus	3.15e-05	0.000207	CcSEcCtD
Thalidomide—Pruritus—Hydrocortisone—systemic lupus erythematosus	3.14e-05	0.000207	CcSEcCtD
Thalidomide—Ill-defined disorder—Methotrexate—systemic lupus erythematosus	3.14e-05	0.000206	CcSEcCtD
Thalidomide—Headache—Cyclosporine—systemic lupus erythematosus	3.13e-05	0.000206	CcSEcCtD
Thalidomide—Anaemia—Methotrexate—systemic lupus erythematosus	3.13e-05	0.000206	CcSEcCtD
Thalidomide—Feeling abnormal—Betamethasone—systemic lupus erythematosus	3.13e-05	0.000205	CcSEcCtD
Thalidomide—Feeling abnormal—Dexamethasone—systemic lupus erythematosus	3.13e-05	0.000205	CcSEcCtD
Thalidomide—Gastrointestinal pain—Dexamethasone—systemic lupus erythematosus	3.11e-05	0.000204	CcSEcCtD
Thalidomide—Gastrointestinal pain—Betamethasone—systemic lupus erythematosus	3.11e-05	0.000204	CcSEcCtD
Thalidomide—Vomiting—Mycophenolate mofetil—systemic lupus erythematosus	3.1e-05	0.000204	CcSEcCtD
Thalidomide—Hypersensitivity—Triamcinolone—systemic lupus erythematosus	3.08e-05	0.000202	CcSEcCtD
Thalidomide—Hypersensitivity—Methylprednisolone—systemic lupus erythematosus	3.08e-05	0.000202	CcSEcCtD
Thalidomide—Rash—Mycophenolate mofetil—systemic lupus erythematosus	3.08e-05	0.000202	CcSEcCtD
Thalidomide—Dermatitis—Mycophenolate mofetil—systemic lupus erythematosus	3.07e-05	0.000202	CcSEcCtD
Thalidomide—Headache—Mycophenolate mofetil—systemic lupus erythematosus	3.06e-05	0.000201	CcSEcCtD
Thalidomide—Malaise—Methotrexate—systemic lupus erythematosus	3.05e-05	0.000201	CcSEcCtD
Thalidomide—Vertigo—Methotrexate—systemic lupus erythematosus	3.04e-05	0.0002	CcSEcCtD
Thalidomide—Diarrhoea—Hydrocortisone—systemic lupus erythematosus	3.04e-05	0.0002	CcSEcCtD
Thalidomide—Leukopenia—Methotrexate—systemic lupus erythematosus	3.03e-05	0.000199	CcSEcCtD
Thalidomide—Urticaria—Dexamethasone—systemic lupus erythematosus	3.02e-05	0.000198	CcSEcCtD
Thalidomide—Urticaria—Betamethasone—systemic lupus erythematosus	3.02e-05	0.000198	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Prednisone—systemic lupus erythematosus	3.01e-05	0.000198	CcSEcCtD
Thalidomide—Dizziness—Prednisolone—systemic lupus erythematosus	3.01e-05	0.000198	CcSEcCtD
Thalidomide—Asthenia—Triamcinolone—systemic lupus erythematosus	3e-05	0.000197	CcSEcCtD
Thalidomide—Abdominal pain—Dexamethasone—systemic lupus erythematosus	3e-05	0.000197	CcSEcCtD
Thalidomide—Abdominal pain—Betamethasone—systemic lupus erythematosus	3e-05	0.000197	CcSEcCtD
Thalidomide—Body temperature increased—Dexamethasone—systemic lupus erythematosus	3e-05	0.000197	CcSEcCtD
Thalidomide—Body temperature increased—Betamethasone—systemic lupus erythematosus	3e-05	0.000197	CcSEcCtD
Thalidomide—Asthenia—Methylprednisolone—systemic lupus erythematosus	3e-05	0.000197	CcSEcCtD
Thalidomide—Insomnia—Prednisone—systemic lupus erythematosus	2.99e-05	0.000196	CcSEcCtD
Thalidomide—Nausea—Cyclosporine—systemic lupus erythematosus	2.97e-05	0.000195	CcSEcCtD
Thalidomide—Paraesthesia—Prednisone—systemic lupus erythematosus	2.97e-05	0.000195	CcSEcCtD
Thalidomide—Pruritus—Triamcinolone—systemic lupus erythematosus	2.96e-05	0.000194	CcSEcCtD
Thalidomide—Cough—Methotrexate—systemic lupus erythematosus	2.96e-05	0.000194	CcSEcCtD
Thalidomide—Pruritus—Methylprednisolone—systemic lupus erythematosus	2.95e-05	0.000194	CcSEcCtD
Thalidomide—Dizziness—Hydrocortisone—systemic lupus erythematosus	2.94e-05	0.000193	CcSEcCtD
Thalidomide—Convulsion—Methotrexate—systemic lupus erythematosus	2.93e-05	0.000193	CcSEcCtD
Thalidomide—Dyspepsia—Prednisone—systemic lupus erythematosus	2.91e-05	0.000191	CcSEcCtD
Thalidomide—Nausea—Mycophenolate mofetil—systemic lupus erythematosus	2.9e-05	0.00019	CcSEcCtD
Thalidomide—Arthralgia—Methotrexate—systemic lupus erythematosus	2.88e-05	0.000189	CcSEcCtD
Thalidomide—Chest pain—Methotrexate—systemic lupus erythematosus	2.88e-05	0.000189	CcSEcCtD
Thalidomide—Myalgia—Methotrexate—systemic lupus erythematosus	2.88e-05	0.000189	CcSEcCtD
Thalidomide—Decreased appetite—Prednisone—systemic lupus erythematosus	2.87e-05	0.000189	CcSEcCtD
Thalidomide—Rash—Prednisolone—systemic lupus erythematosus	2.87e-05	0.000188	CcSEcCtD
Thalidomide—Dermatitis—Prednisolone—systemic lupus erythematosus	2.87e-05	0.000188	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic lupus erythematosus	2.86e-05	0.000188	CcSEcCtD
Thalidomide—Diarrhoea—Methylprednisolone—systemic lupus erythematosus	2.86e-05	0.000188	CcSEcCtD
Thalidomide—Fatigue—Prednisone—systemic lupus erythematosus	2.85e-05	0.000187	CcSEcCtD
Thalidomide—Headache—Prednisolone—systemic lupus erythematosus	2.85e-05	0.000187	CcSEcCtD
Thalidomide—Discomfort—Methotrexate—systemic lupus erythematosus	2.85e-05	0.000187	CcSEcCtD
Thalidomide—Constipation—Prednisone—systemic lupus erythematosus	2.83e-05	0.000186	CcSEcCtD
Thalidomide—Vomiting—Hydrocortisone—systemic lupus erythematosus	2.83e-05	0.000186	CcSEcCtD
Thalidomide—Rash—Hydrocortisone—systemic lupus erythematosus	2.8e-05	0.000184	CcSEcCtD
Thalidomide—Dermatitis—Hydrocortisone—systemic lupus erythematosus	2.8e-05	0.000184	CcSEcCtD
Thalidomide—Confusional state—Methotrexate—systemic lupus erythematosus	2.79e-05	0.000183	CcSEcCtD
Thalidomide—Headache—Hydrocortisone—systemic lupus erythematosus	2.78e-05	0.000183	CcSEcCtD
Thalidomide—Dizziness—Triamcinolone—systemic lupus erythematosus	2.77e-05	0.000182	CcSEcCtD
Thalidomide—Dizziness—Methylprednisolone—systemic lupus erythematosus	2.76e-05	0.000181	CcSEcCtD
Thalidomide—Infection—Methotrexate—systemic lupus erythematosus	2.75e-05	0.00018	CcSEcCtD
Thalidomide—Feeling abnormal—Prednisone—systemic lupus erythematosus	2.73e-05	0.000179	CcSEcCtD
Thalidomide—Asthenia—Dexamethasone—systemic lupus erythematosus	2.72e-05	0.000179	CcSEcCtD
Thalidomide—Asthenia—Betamethasone—systemic lupus erythematosus	2.72e-05	0.000179	CcSEcCtD
Thalidomide—Nervous system disorder—Methotrexate—systemic lupus erythematosus	2.71e-05	0.000178	CcSEcCtD
Thalidomide—Thrombocytopenia—Methotrexate—systemic lupus erythematosus	2.71e-05	0.000178	CcSEcCtD
Thalidomide—Gastrointestinal pain—Prednisone—systemic lupus erythematosus	2.7e-05	0.000178	CcSEcCtD
Thalidomide—Nausea—Prednisolone—systemic lupus erythematosus	2.7e-05	0.000178	CcSEcCtD
Thalidomide—Pruritus—Dexamethasone—systemic lupus erythematosus	2.69e-05	0.000176	CcSEcCtD
Thalidomide—Pruritus—Betamethasone—systemic lupus erythematosus	2.69e-05	0.000176	CcSEcCtD
Thalidomide—Skin disorder—Methotrexate—systemic lupus erythematosus	2.68e-05	0.000176	CcSEcCtD
Thalidomide—Hyperhidrosis—Methotrexate—systemic lupus erythematosus	2.67e-05	0.000175	CcSEcCtD
Thalidomide—Vomiting—Triamcinolone—systemic lupus erythematosus	2.66e-05	0.000175	CcSEcCtD
Thalidomide—Vomiting—Methylprednisolone—systemic lupus erythematosus	2.66e-05	0.000174	CcSEcCtD
Thalidomide—Nausea—Hydrocortisone—systemic lupus erythematosus	2.64e-05	0.000173	CcSEcCtD
Thalidomide—Rash—Triamcinolone—systemic lupus erythematosus	2.64e-05	0.000173	CcSEcCtD
Thalidomide—Dermatitis—Triamcinolone—systemic lupus erythematosus	2.64e-05	0.000173	CcSEcCtD
Thalidomide—Anorexia—Methotrexate—systemic lupus erythematosus	2.63e-05	0.000173	CcSEcCtD
Thalidomide—Rash—Methylprednisolone—systemic lupus erythematosus	2.63e-05	0.000173	CcSEcCtD
Thalidomide—Dermatitis—Methylprednisolone—systemic lupus erythematosus	2.63e-05	0.000173	CcSEcCtD
Thalidomide—Urticaria—Prednisone—systemic lupus erythematosus	2.63e-05	0.000173	CcSEcCtD
Thalidomide—Headache—Triamcinolone—systemic lupus erythematosus	2.62e-05	0.000172	CcSEcCtD
Thalidomide—Headache—Methylprednisolone—systemic lupus erythematosus	2.62e-05	0.000172	CcSEcCtD
Thalidomide—Body temperature increased—Prednisone—systemic lupus erythematosus	2.61e-05	0.000172	CcSEcCtD
Thalidomide—Abdominal pain—Prednisone—systemic lupus erythematosus	2.61e-05	0.000172	CcSEcCtD
Thalidomide—Diarrhoea—Dexamethasone—systemic lupus erythematosus	2.6e-05	0.000171	CcSEcCtD
Thalidomide—Diarrhoea—Betamethasone—systemic lupus erythematosus	2.6e-05	0.000171	CcSEcCtD
Thalidomide—Hypotension—Methotrexate—systemic lupus erythematosus	2.58e-05	0.00017	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Methotrexate—systemic lupus erythematosus	2.52e-05	0.000165	CcSEcCtD
Thalidomide—Dizziness—Dexamethasone—systemic lupus erythematosus	2.51e-05	0.000165	CcSEcCtD
Thalidomide—Dizziness—Betamethasone—systemic lupus erythematosus	2.51e-05	0.000165	CcSEcCtD
Thalidomide—Insomnia—Methotrexate—systemic lupus erythematosus	2.5e-05	0.000164	CcSEcCtD
Thalidomide—Nausea—Triamcinolone—systemic lupus erythematosus	2.49e-05	0.000163	CcSEcCtD
Thalidomide—Paraesthesia—Methotrexate—systemic lupus erythematosus	2.48e-05	0.000163	CcSEcCtD
Thalidomide—Nausea—Methylprednisolone—systemic lupus erythematosus	2.48e-05	0.000163	CcSEcCtD
Thalidomide—Dyspnoea—Methotrexate—systemic lupus erythematosus	2.46e-05	0.000162	CcSEcCtD
Thalidomide—Somnolence—Methotrexate—systemic lupus erythematosus	2.46e-05	0.000161	CcSEcCtD
Thalidomide—Hypersensitivity—Prednisone—systemic lupus erythematosus	2.44e-05	0.00016	CcSEcCtD
Thalidomide—Dyspepsia—Methotrexate—systemic lupus erythematosus	2.43e-05	0.00016	CcSEcCtD
Thalidomide—Vomiting—Dexamethasone—systemic lupus erythematosus	2.41e-05	0.000159	CcSEcCtD
Thalidomide—Vomiting—Betamethasone—systemic lupus erythematosus	2.41e-05	0.000159	CcSEcCtD
Thalidomide—Decreased appetite—Methotrexate—systemic lupus erythematosus	2.4e-05	0.000158	CcSEcCtD
Thalidomide—Rash—Dexamethasone—systemic lupus erythematosus	2.39e-05	0.000157	CcSEcCtD
Thalidomide—Rash—Betamethasone—systemic lupus erythematosus	2.39e-05	0.000157	CcSEcCtD
Thalidomide—Dermatitis—Dexamethasone—systemic lupus erythematosus	2.39e-05	0.000157	CcSEcCtD
Thalidomide—Dermatitis—Betamethasone—systemic lupus erythematosus	2.39e-05	0.000157	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Methotrexate—systemic lupus erythematosus	2.39e-05	0.000157	CcSEcCtD
Thalidomide—Fatigue—Methotrexate—systemic lupus erythematosus	2.38e-05	0.000156	CcSEcCtD
Thalidomide—Headache—Dexamethasone—systemic lupus erythematosus	2.38e-05	0.000156	CcSEcCtD
Thalidomide—Headache—Betamethasone—systemic lupus erythematosus	2.38e-05	0.000156	CcSEcCtD
Thalidomide—Asthenia—Prednisone—systemic lupus erythematosus	2.37e-05	0.000156	CcSEcCtD
Thalidomide—Pain—Methotrexate—systemic lupus erythematosus	2.36e-05	0.000155	CcSEcCtD
Thalidomide—Pruritus—Prednisone—systemic lupus erythematosus	2.34e-05	0.000154	CcSEcCtD
Thalidomide—Feeling abnormal—Methotrexate—systemic lupus erythematosus	2.28e-05	0.00015	CcSEcCtD
Thalidomide—Diarrhoea—Prednisone—systemic lupus erythematosus	2.26e-05	0.000149	CcSEcCtD
Thalidomide—Gastrointestinal pain—Methotrexate—systemic lupus erythematosus	2.26e-05	0.000148	CcSEcCtD
Thalidomide—Nausea—Dexamethasone—systemic lupus erythematosus	2.26e-05	0.000148	CcSEcCtD
Thalidomide—Nausea—Betamethasone—systemic lupus erythematosus	2.26e-05	0.000148	CcSEcCtD
Thalidomide—Urticaria—Methotrexate—systemic lupus erythematosus	2.2e-05	0.000144	CcSEcCtD
Thalidomide—Dizziness—Prednisone—systemic lupus erythematosus	2.19e-05	0.000144	CcSEcCtD
Thalidomide—Abdominal pain—Methotrexate—systemic lupus erythematosus	2.18e-05	0.000143	CcSEcCtD
Thalidomide—Body temperature increased—Methotrexate—systemic lupus erythematosus	2.18e-05	0.000143	CcSEcCtD
Thalidomide—Vomiting—Prednisone—systemic lupus erythematosus	2.1e-05	0.000138	CcSEcCtD
Thalidomide—Rash—Prednisone—systemic lupus erythematosus	2.09e-05	0.000137	CcSEcCtD
Thalidomide—Dermatitis—Prednisone—systemic lupus erythematosus	2.08e-05	0.000137	CcSEcCtD
Thalidomide—Headache—Prednisone—systemic lupus erythematosus	2.07e-05	0.000136	CcSEcCtD
Thalidomide—Hypersensitivity—Methotrexate—systemic lupus erythematosus	2.04e-05	0.000134	CcSEcCtD
Thalidomide—Asthenia—Methotrexate—systemic lupus erythematosus	1.98e-05	0.00013	CcSEcCtD
Thalidomide—Nausea—Prednisone—systemic lupus erythematosus	1.96e-05	0.000129	CcSEcCtD
Thalidomide—Pruritus—Methotrexate—systemic lupus erythematosus	1.96e-05	0.000128	CcSEcCtD
Thalidomide—Diarrhoea—Methotrexate—systemic lupus erythematosus	1.89e-05	0.000124	CcSEcCtD
Thalidomide—Dizziness—Methotrexate—systemic lupus erythematosus	1.83e-05	0.00012	CcSEcCtD
Thalidomide—Vomiting—Methotrexate—systemic lupus erythematosus	1.76e-05	0.000115	CcSEcCtD
Thalidomide—Rash—Methotrexate—systemic lupus erythematosus	1.74e-05	0.000114	CcSEcCtD
Thalidomide—Dermatitis—Methotrexate—systemic lupus erythematosus	1.74e-05	0.000114	CcSEcCtD
Thalidomide—Headache—Methotrexate—systemic lupus erythematosus	1.73e-05	0.000114	CcSEcCtD
Thalidomide—Nausea—Methotrexate—systemic lupus erythematosus	1.64e-05	0.000108	CcSEcCtD
Thalidomide—FGFR2—Disease—JUNB—systemic lupus erythematosus	1.3e-05	0.000109	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PRL—systemic lupus erythematosus	1.29e-05	0.000109	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-DQA1—systemic lupus erythematosus	1.29e-05	0.000109	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—IL6—systemic lupus erythematosus	1.28e-05	0.000107	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CSK—systemic lupus erythematosus	1.26e-05	0.000106	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TNF—systemic lupus erythematosus	1.25e-05	0.000105	CbGpPWpGaD
Thalidomide—PTGS2—Disease—XRCC6—systemic lupus erythematosus	1.25e-05	0.000105	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—TYK2—systemic lupus erythematosus	1.23e-05	0.000103	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-DQA1—systemic lupus erythematosus	1.23e-05	0.000103	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NCF2—systemic lupus erythematosus	1.22e-05	0.000102	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—PPARG—systemic lupus erythematosus	1.21e-05	0.000102	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—LYN—systemic lupus erythematosus	1.21e-05	0.000102	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-DQB1—systemic lupus erythematosus	1.21e-05	0.000102	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—systemic lupus erythematosus	1.2e-05	0.0001	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PRL—systemic lupus erythematosus	1.19e-05	0.0001	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SH2B3—systemic lupus erythematosus	1.19e-05	9.98e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—TYK2—systemic lupus erythematosus	1.17e-05	9.82e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NCF2—systemic lupus erythematosus	1.16e-05	9.72e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—LYN—systemic lupus erythematosus	1.15e-05	9.65e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-DQB1—systemic lupus erythematosus	1.15e-05	9.64e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL18—systemic lupus erythematosus	1.15e-05	9.63e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD40LG—systemic lupus erythematosus	1.14e-05	9.6e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD8A—systemic lupus erythematosus	1.13e-05	9.49e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SH2B3—systemic lupus erythematosus	1.13e-05	9.47e-05	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—IL6—systemic lupus erythematosus	1.13e-05	9.46e-05	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CD4—systemic lupus erythematosus	1.11e-05	9.36e-05	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—systemic lupus erythematosus	1.1e-05	9.27e-05	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—MMP9—systemic lupus erythematosus	1.1e-05	9.23e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—JAK1—systemic lupus erythematosus	1.09e-05	9.16e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL18—systemic lupus erythematosus	1.09e-05	9.14e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD40LG—systemic lupus erythematosus	1.08e-05	9.11e-05	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL6—systemic lupus erythematosus	1.07e-05	9.03e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD8A—systemic lupus erythematosus	1.07e-05	9e-05	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CD4—systemic lupus erythematosus	1.07e-05	8.99e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—TYK2—systemic lupus erythematosus	1.06e-05	8.93e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—NAT2—systemic lupus erythematosus	1.06e-05	8.92e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	1.06e-05	8.91e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CD4—systemic lupus erythematosus	1.06e-05	8.88e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—IL6—systemic lupus erythematosus	1.06e-05	8.87e-05	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—systemic lupus erythematosus	1.05e-05	8.82e-05	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CDKN1B—systemic lupus erythematosus	1.05e-05	8.8e-05	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—EP300—systemic lupus erythematosus	1.04e-05	8.75e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—JAK1—systemic lupus erythematosus	1.03e-05	8.69e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL2RA—systemic lupus erythematosus	1.02e-05	8.55e-05	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CD4—systemic lupus erythematosus	1.01e-05	8.53e-05	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—IL6—systemic lupus erythematosus	1.01e-05	8.49e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—C3—systemic lupus erythematosus	1.01e-05	8.48e-05	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CDKN1B—systemic lupus erythematosus	1.01e-05	8.45e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—IL6—systemic lupus erythematosus	1e-05	8.42e-05	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—systemic lupus erythematosus	9.94e-06	8.35e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CDKN1B—systemic lupus erythematosus	9.94e-06	8.35e-05	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—VEGFA—systemic lupus erythematosus	9.86e-06	8.29e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—systemic lupus erythematosus	9.77e-06	8.2e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CXCL12—systemic lupus erythematosus	9.75e-06	8.19e-05	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CDKN1A—systemic lupus erythematosus	9.67e-06	8.12e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL2RA—systemic lupus erythematosus	9.66e-06	8.12e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CRP—systemic lupus erythematosus	9.61e-06	8.07e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—C3—systemic lupus erythematosus	9.58e-06	8.05e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—JUNB—systemic lupus erythematosus	9.57e-06	8.04e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—JAK1—systemic lupus erythematosus	9.55e-06	8.02e-05	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CDKN1B—systemic lupus erythematosus	9.54e-06	8.02e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	9.42e-06	7.91e-05	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CDKN1A—systemic lupus erythematosus	9.28e-06	7.8e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CXCL12—systemic lupus erythematosus	9.25e-06	7.77e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—TLR4—systemic lupus erythematosus	9.21e-06	7.74e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HIST2H2AC—systemic lupus erythematosus	9.2e-06	7.73e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-DRB1—systemic lupus erythematosus	9.2e-06	7.73e-05	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—EP300—systemic lupus erythematosus	9.2e-06	7.73e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CDKN1A—systemic lupus erythematosus	9.17e-06	7.7e-05	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—systemic lupus erythematosus	9.12e-06	7.66e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CRP—systemic lupus erythematosus	9.11e-06	7.66e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—RASGRP1—systemic lupus erythematosus	9.09e-06	7.64e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—JUNB—systemic lupus erythematosus	9.08e-06	7.63e-05	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TGFB1—systemic lupus erythematosus	9.05e-06	7.6e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CCR5—systemic lupus erythematosus	9.05e-06	7.6e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CSK—systemic lupus erythematosus	8.97e-06	7.54e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PRL—systemic lupus erythematosus	8.81e-06	7.4e-05	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CDKN1A—systemic lupus erythematosus	8.81e-06	7.4e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—TLR4—systemic lupus erythematosus	8.74e-06	7.34e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-DRB1—systemic lupus erythematosus	8.73e-06	7.33e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—EP300—systemic lupus erythematosus	8.73e-06	7.33e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—RASGRP1—systemic lupus erythematosus	8.62e-06	7.25e-05	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—systemic lupus erythematosus	8.52e-06	7.16e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD80—systemic lupus erythematosus	8.5e-06	7.14e-05	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TNF—systemic lupus erythematosus	8.45e-06	7.1e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	8.44e-06	7.09e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CD247—systemic lupus erythematosus	8.43e-06	7.08e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—NAT2—systemic lupus erythematosus	8.43e-06	7.08e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MMP9—systemic lupus erythematosus	8.37e-06	7.03e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PRL—systemic lupus erythematosus	8.36e-06	7.03e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NCF2—systemic lupus erythematosus	8.2e-06	6.89e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD80—systemic lupus erythematosus	8.06e-06	6.77e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—EP300—systemic lupus erythematosus	7.93e-06	6.67e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—NAT2—systemic lupus erythematosus	7.93e-06	6.66e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—NAT2—systemic lupus erythematosus	7.92e-06	6.65e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	7.7e-06	6.47e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	7.59e-06	6.37e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—VEGFA—systemic lupus erythematosus	7.51e-06	6.31e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—NAT2—systemic lupus erythematosus	7.48e-06	6.28e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CD80—systemic lupus erythematosus	7.45e-06	6.25e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—TYK2—systemic lupus erythematosus	7.17e-06	6.03e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—JAK1—systemic lupus erythematosus	7.05e-06	5.92e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	7.03e-06	5.9e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—TGFB1—systemic lupus erythematosus	6.9e-06	5.79e-05	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—IL6—systemic lupus erythematosus	6.82e-06	5.73e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—TYK2—systemic lupus erythematosus	6.81e-06	5.72e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IFNG—systemic lupus erythematosus	6.72e-06	5.64e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	6.7e-06	5.63e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—JAK1—systemic lupus erythematosus	6.69e-06	5.62e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCR5—systemic lupus erythematosus	6.68e-06	5.61e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	6.64e-06	5.58e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL2RA—systemic lupus erythematosus	6.58e-06	5.53e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—C3—systemic lupus erythematosus	6.53e-06	5.48e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD4—systemic lupus erythematosus	6.49e-06	5.45e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—JUNB—systemic lupus erythematosus	6.44e-06	5.41e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IFNG—systemic lupus erythematosus	6.37e-06	5.35e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCR5—systemic lupus erythematosus	6.34e-06	5.32e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TYK2—systemic lupus erythematosus	6.28e-06	5.28e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL2RA—systemic lupus erythematosus	6.25e-06	5.25e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—C3—systemic lupus erythematosus	6.19e-06	5.2e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NOS3—systemic lupus erythematosus	6.17e-06	5.18e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD4—systemic lupus erythematosus	6.16e-06	5.17e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NAT2—systemic lupus erythematosus	6.12e-06	5.14e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CDKN1B—systemic lupus erythematosus	6.1e-06	5.12e-05	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—IL6—systemic lupus erythematosus	6.02e-06	5.06e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	6.02e-06	5.06e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	6e-06	5.04e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL2—systemic lupus erythematosus	5.97e-06	5.02e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—RXRA—systemic lupus erythematosus	5.95e-06	5e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	5.94e-06	4.99e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PRL—systemic lupus erythematosus	5.93e-06	4.98e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CDKN1B—systemic lupus erythematosus	5.79e-06	4.86e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—F2—systemic lupus erythematosus	5.73e-06	4.81e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—IL6—systemic lupus erythematosus	5.72e-06	4.8e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CD4—systemic lupus erythematosus	5.68e-06	4.77e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL2—systemic lupus erythematosus	5.66e-06	4.76e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTGS2—systemic lupus erythematosus	5.64e-06	4.74e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CDKN1A—systemic lupus erythematosus	5.63e-06	4.73e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NAT2—systemic lupus erythematosus	5.58e-06	4.69e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	5.52e-06	4.64e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CD80—systemic lupus erythematosus	5.49e-06	4.62e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—F2—systemic lupus erythematosus	5.44e-06	4.57e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—EP300—systemic lupus erythematosus	5.36e-06	4.5e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	5.35e-06	4.49e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CDKN1B—systemic lupus erythematosus	5.34e-06	4.49e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CDKN1A—systemic lupus erythematosus	5.34e-06	4.49e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CD80—systemic lupus erythematosus	5.21e-06	4.38e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—IL6—systemic lupus erythematosus	5.2e-06	4.37e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCL2—systemic lupus erythematosus	5.11e-06	4.29e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—EP300—systemic lupus erythematosus	5.08e-06	4.27e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CDKN1A—systemic lupus erythematosus	4.93e-06	4.14e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	4.86e-06	4.09e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCL2—systemic lupus erythematosus	4.85e-06	4.07e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NAT2—systemic lupus erythematosus	4.77e-06	4.01e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—JAK1—systemic lupus erythematosus	4.74e-06	3.98e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—RXRA—systemic lupus erythematosus	4.72e-06	3.97e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—EP300—systemic lupus erythematosus	4.69e-06	3.94e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	4.68e-06	3.93e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TYK2—systemic lupus erythematosus	4.64e-06	3.9e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NOS3—systemic lupus erythematosus	4.55e-06	3.82e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CCR5—systemic lupus erythematosus	4.49e-06	3.78e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—RXRA—systemic lupus erythematosus	4.45e-06	3.74e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—RXRA—systemic lupus erythematosus	4.44e-06	3.73e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	4.44e-06	3.73e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TYK2—systemic lupus erythematosus	4.4e-06	3.7e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	4.38e-06	3.68e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	4.37e-06	3.67e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NOS3—systemic lupus erythematosus	4.32e-06	3.63e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—RXRA—systemic lupus erythematosus	4.19e-06	3.52e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TGFB1—systemic lupus erythematosus	4.08e-06	3.43e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	3.99e-06	3.35e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CDKN1B—systemic lupus erythematosus	3.94e-06	3.31e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	3.89e-06	3.27e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL2—systemic lupus erythematosus	3.86e-06	3.24e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	3.83e-06	3.21e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	3.79e-06	3.18e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PPARG—systemic lupus erythematosus	3.76e-06	3.16e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CDKN1B—systemic lupus erythematosus	3.74e-06	3.14e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CD80—systemic lupus erythematosus	3.7e-06	3.11e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL2—systemic lupus erythematosus	3.66e-06	3.08e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MMP9—systemic lupus erythematosus	3.65e-06	3.07e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CDKN1A—systemic lupus erythematosus	3.64e-06	3.06e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6—systemic lupus erythematosus	3.51e-06	2.95e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	3.49e-06	2.93e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MMP9—systemic lupus erythematosus	3.47e-06	2.91e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EP300—systemic lupus erythematosus	3.46e-06	2.91e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CDKN1A—systemic lupus erythematosus	3.45e-06	2.9e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—RXRA—systemic lupus erythematosus	3.43e-06	2.88e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	3.41e-06	2.86e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ALB—systemic lupus erythematosus	3.38e-06	2.84e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6—systemic lupus erythematosus	3.33e-06	2.8e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EP300—systemic lupus erythematosus	3.29e-06	2.76e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VEGFA—systemic lupus erythematosus	3.28e-06	2.76e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—NOS3—systemic lupus erythematosus	3.23e-06	2.72e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	3.18e-06	2.67e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—RXRA—systemic lupus erythematosus	3.13e-06	2.63e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TYK2—systemic lupus erythematosus	3.12e-06	2.62e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VEGFA—systemic lupus erythematosus	3.11e-06	2.61e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6—systemic lupus erythematosus	3.07e-06	2.58e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS3—systemic lupus erythematosus	3.06e-06	2.57e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TGFB1—systemic lupus erythematosus	3.01e-06	2.53e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PPARG—systemic lupus erythematosus	2.98e-06	2.51e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	2.98e-06	2.5e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—systemic lupus erythematosus	2.96e-06	2.48e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	2.9e-06	2.44e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TGFB1—systemic lupus erythematosus	2.86e-06	2.4e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CD4—systemic lupus erythematosus	2.82e-06	2.37e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPARG—systemic lupus erythematosus	2.81e-06	2.36e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPARG—systemic lupus erythematosus	2.8e-06	2.35e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ALB—systemic lupus erythematosus	2.68e-06	2.25e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—RXRA—systemic lupus erythematosus	2.67e-06	2.25e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CDKN1B—systemic lupus erythematosus	2.65e-06	2.23e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPARG—systemic lupus erythematosus	2.65e-06	2.22e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—NOS3—systemic lupus erythematosus	2.57e-06	2.16e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ALB—systemic lupus erythematosus	2.52e-06	2.12e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ALB—systemic lupus erythematosus	2.52e-06	2.12e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	2.48e-06	2.08e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—EP300—systemic lupus erythematosus	2.46e-06	2.07e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CDKN1A—systemic lupus erythematosus	2.45e-06	2.06e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—NOS3—systemic lupus erythematosus	2.42e-06	2.03e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—NOS3—systemic lupus erythematosus	2.41e-06	2.02e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ALB—systemic lupus erythematosus	2.38e-06	2e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EP300—systemic lupus erythematosus	2.33e-06	1.96e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—NOS3—systemic lupus erythematosus	2.28e-06	1.91e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6—systemic lupus erythematosus	2.27e-06	1.91e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—systemic lupus erythematosus	2.21e-06	1.86e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—systemic lupus erythematosus	2.2e-06	1.85e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPARG—systemic lupus erythematosus	2.17e-06	1.82e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6—systemic lupus erythematosus	2.15e-06	1.81e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—systemic lupus erythematosus	2.08e-06	1.75e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TGFB1—systemic lupus erythematosus	2.03e-06	1.7e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPARG—systemic lupus erythematosus	1.98e-06	1.66e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—EP300—systemic lupus erythematosus	1.95e-06	1.64e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALB—systemic lupus erythematosus	1.95e-06	1.64e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NOS3—systemic lupus erythematosus	1.86e-06	1.57e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—EP300—systemic lupus erythematosus	1.84e-06	1.54e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—EP300—systemic lupus erythematosus	1.83e-06	1.54e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALB—systemic lupus erythematosus	1.78e-06	1.49e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—EP300—systemic lupus erythematosus	1.73e-06	1.46e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—systemic lupus erythematosus	1.7e-06	1.43e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NOS3—systemic lupus erythematosus	1.7e-06	1.43e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPARG—systemic lupus erythematosus	1.69e-06	1.42e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—systemic lupus erythematosus	1.55e-06	1.31e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6—systemic lupus erythematosus	1.53e-06	1.28e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALB—systemic lupus erythematosus	1.52e-06	1.28e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NOS3—systemic lupus erythematosus	1.45e-06	1.22e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—EP300—systemic lupus erythematosus	1.42e-06	1.19e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—systemic lupus erythematosus	1.33e-06	1.12e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—EP300—systemic lupus erythematosus	1.29e-06	1.09e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—EP300—systemic lupus erythematosus	1.1e-06	9.28e-06	CbGpPWpGaD
